D-0441-2023 Class II Terminated

Recalled by Teva Pharmaceuticals USA Inc — Parsippany, NJ

FDA drug recall D-0441-2023 was initiated by Teva Pharmaceuticals USA Inc on Feb 22, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. The recall status is terminated (terminated Dec 6, 2023). Affected quantity: 12,044 Bottles.

Recall details

Product Type
Drugs
Report Date
Mar 15, 2023
Initiation Date
Feb 22, 2023
Termination Date
Dec 6, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,044 Bottles

Product description

Metformin hydrochloride Extended-Release Tablets, 1000 mg, 60-count bottle, RX only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 00591-2720-60

Reason for recall

CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Distribution pattern

CA

Code information

Lot #: 1410946A; Exp. 06/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0441-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0441-2023. Report a data issue: hello@regdatalab.com.